Daré Bioscience

4:15 PM - 4:30 PM, Tuesday, March 5, 2019 ・ 2nd Floor
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s sexual health, vaginal health, fertility, and contraception. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-class candidates in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring; and Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder utilizing the active ingredient in Viagra®, as well as a proprietary solution-to-gel formulation of clindamycin to treat bacterial vaginosis via a single application, DARE-BV1.
Ticker:
DARE
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
DARE-BV1, Ovaprene, Sildenafil Cream
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
6